About Ciclesonide

Pharmacological effects

Ciclesonide directly into the lungs, to locate activation, with the ideal inhaled corticosteroids numerous features, including the glucocorticoid receptor with high affinity, better local anti-inflammatory activity and long-lasting effects, complete first pass effect and high plasma protein binding rate of favorable play better efficacy and reduce systemic adverse reactions. For mild to moderate asthma 160μg, once daily for up to well controlled. Clinical data show that compared with other inhaled corticosteroids better security, including local adverse events and no decrease cortisol inhibition. Ciclesonide is another effective asthma treatment option.

CLINICAL STUDIES

According to the Canadian study, once daily ciclesonide (ciclesonide) - an inhaled corticosteroid, activation in the lungs, there is almost no systemic effect - controlled adult patients with mild to moderate persistent asthma. This treatment rarely cause adverse events, but also did not affect plasma cortisol levels.

University of Toronto Western Hospital Qiapu Man (Kenneth R. Chapman) and his colleagues randomly assigned patients in two weeks or after insertion of ciclesonide 160g (n = 107), or 640g g (n = 112) or placebo ( n = 110) treated. Of the 12-week trial period, two ciclesonide group no significant or clinically meaningful differences in March of "allergic" magazine (Allergy 2005; 60:330-337) reported on.

Ciclesonide group maximum peak expiratory flow, forced expiratory volume in one second and forced vital capacity remained stable, but the placebo group decreased. Asthma symptoms during the day when the change from baseline and the use of rescue drugs, the ciclesonide group than the placebo group. 63% of the placebo group had no effect, ciclesonide group of 30-31% (p <0.0001). Three groups of plasma and urine levels of ciclesonide, adverse reactions were similar, nobody risk of oral candidiasis.

In a 52-week randomized, double-blind study of perennial allergic rhinitis, 12 years old, have at least two years, patients with a history of allergic rhinitis were randomized to receive nasal inner ciclesonide (ciclesonide) or placebo for a total of 52 weeks. Studies have shown that the inner ciclesonide nasal reactivity group 24 hours TNSS decreased compared with the placebo group were significantly different, respectively, 2.3 and 1.8 (P <0.001); in the first week of treatment, significant differences between the groups already (P <0.001), throughout the study period checked every four weeks, the situation continue to do so (P <0.05). In addition, ciclesonide group of patients compared with placebo, nasal symptoms score in the entire 52 weeks improved more significantly (P <0.05). In the end, ciclesonide group nose and conjunctivitis quality of life questionnaire improved more significantly than the placebo group.